Differential regulation of the REGγ–proteasome pathway by p53/TGF-β signalling and mutant p53 in cancer cells

Citations Over TimeTop 10% of 2013 papers

Abstract

Proteasome activity is frequently enhanced in cancer to accelerate metastasis and tumorigenesis. REGγ, a proteasome activator known to promote p53/p21/p16 degradation, is often overexpressed in cancer cells. Here we show that p53/TGF-β signalling inhibits the REGγ-20S proteasome pathway by repressing REGγ expression. Smad3 and p53 interact on the REGγ promoter via the p53RE/SBE region. Conversely, mutant p53 binds to the REGγ promoter and recruits p300. Importantly, mutant p53 prevents Smad3/N-CoR complex formation on the REGγ promoter, which enhances the activity of the REGγ-20S proteasome pathway and contributes to mutant p53 gain of function. Depletion of REGγ alters the cellular response to p53/TGF-β signalling in drug resistance, proliferation, cell cycle progression and proteasome activity. Moreover, p53 mutations show a positive correlation with REGγ expression in cancer samples. These findings suggest that targeting REGγ-20S proteasome for cancer therapy may be applicable to human tumours with abnormal p53/Smad protein status. Furthermore, this study demonstrates a link between p53/TGF-β signalling and the REGγ-20S proteasome pathway, and provides insight into the REGγ/p53 feedback loop.

Related Papers

• → The Novel Symbiotic Phenotype of Enhanced-Nodulating Mutant of Lotus japonicus: astray Mutant is an Early Nodulating Mutant with Wider Nodulation Zone(2002)60 cited
• Expression of Smad 2 and Smad 4 proteins in brain tissue following cerebral ischemia/reperfusion in gerbils(2008)
• → Receptors and Signal Transduction for the TGF-beta Related Factors.(1999)1 cited
• The Alteration of Smad 4,Smad 6 and Smad 7 in Pancreatic Cancer and Their Relationship(2005)
• Expression and Effects of Smad_4 and Smad_7 in Human Glioma(2005)